Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Tapering Thrombopoietin Receptor Agonists in Primary Immune Thrombocytopenia: Recommendations Based on the RAND/UCLA Modified Delphi Panel Method

Adam Cuker, MD, Jenny M. Despotovic, DO, Rachael F. Grace, MD, Caroline Kruse, Michele P. Lambert, MD MSTR, Howard Liebman, MD, Roger M. Lyons, MD, Keith R McCrae, MD, Vinod A. Pullarkat, MD, Jeffrey Wasser, MD, David Beenhouwer, MD, Sarah N Gibbs, MPH, Irina Yermilov, MD MPH, MS, Michael S Broder, MD MSHS

Blood (2020) 136 (Supplement 1): 6–8.

https://doi.org/10.1182/blood-2020-133262

Published: 2020

Journal Articles

Rate of Bleeding-Related Episodes (BREs) in Adult Patients with Primary Immune Thrombocytopenic Pupura (ITP): A Population-Based Retrospective Cohort Study of Administrative Medical Claims Data in the United States (US)

Karynsa Cetin, M.P.H, Jeffrey Wasser, MD, Sally Wettten, MSc, Ivy Altomare, MD

Blood (2014) 124 (21): 202.

https://doi.org/10.1182/blood.V124.21.202.202

Published: 2014

Journal Articles

Integrated Analysis of Long Term Safety in Patients (pts) with Chronic Immune Thrombocytopenia (ITP) Treated with Romiplostim.

Douglas B. Cines, MD, Terry B. Gernsheimer, MD, Jeffrey Wasser, MD, Bertrand Godeau, MD, Andrew Provan, MD, Roger M. Lyons, MD, Ivy Altomare, Xuena Wang, PhD, Paul Woodard, MD

Blood (2012) 120 (21): 2185.

https://doi.org/10.1182/blood.V120.21.2185.2185

Published: 2012

Journal Articles

Use of Rituximab in a Study Comparing the Thrombopoietin Mimetic Romiplostim with Standard of Care (SOC) in Patients with Immune Thrombocytopenia (ITP),

Jeffrey Wasser, MD, Ralph Vincent V. Boccia, MD, Roger M. Lyons, MD, Romeo Mandanas, Ingrid Pabinger, Marc Michel IV, Jean-François Viallard, MD-PhD, Xuena Wang, PhD, Richard Lizambri, MD

Blood (2011) 118 (21): 3282.

https://doi.org/10.1182/blood.V118.21.3282.3282

Published: 2011

Journal Articles

Long-Term Efficacy and Safety of Romiplostim for the Treatment of Patients with Chronic Immune Thrombocytopenia (ITP): 5-Year Update From An Open-Label Extension Study.

James B. Bussel, MD, David J Kuter, MD, DPhil, Adrian Newland, MD, FRCP, Joost TM de Wolf, MD, Jeffrey Wasser, MD, Paul Chang, Kun Nie, Dietmar Berger, MD, PhD

Blood (2009) 114 (22): 681.

https://doi.org/10.1182/blood.V114.22.681.681

Published: 2009

Journal Articles

Long-Term Treatment with Romiplostim in Patients with Chronic Immune Thrombocytopenic Purpura (ITP): 3-Year Update from An Open-Label Extension Study

David J Kuter, MD, DPhil, James B Bussel, MD, Adrian Newland, MD, FRCP, Joost TM de Wolf, MD, Troy Guthrie, MD, Jeffrey Wasser, MD, Lara Gehl, Kun Nie, PhD, Dietmar Berger, MD, PhD

Blood (2008) 112 (11): 402.

https://doi.org/10.1182/blood.V112.11.402.402

Published: 2008

Journal Articles

Long-Term Dosing of AMG 531 in Thrombocytopenic Patients with Immune Thrombocytopenic Purpura: 48-Week Update.

David Kuter, James Bussel, James George, Louis Aledort, Alan Lichtin, Roger Lyons, Jorge Nieva, Jeffrey Wasser, Emanuelle Bourgeois, Mies Kappers-Klunne, Francois Lefrere, Martin Schipperus, Reggie Kelly, Jenny Christal, Matthew Guo, Janet Nichol

Blood (2006) 108 (11): 476.

https://doi.org/10.1182/blood.V108.11.476.476

Published: 2006

NARROW

Tapering Thrombopoietin Receptor Agonists in Primary Immune Thrombocytopenia: Recommendations Based on the RAND/UCLA Modified Delphi Panel Method

Rate of Bleeding-Related Episodes (BREs) in Adult Patients with Primary Immune Thrombocytopenic Pupura (ITP): A Population-Based Retrospective Cohort Study of Administrative Medical Claims Data in the United States (US)

Integrated Analysis of Long Term Safety in Patients (pts) with Chronic Immune Thrombocytopenia (ITP) Treated with Romiplostim.

Use of Rituximab in a Study Comparing the Thrombopoietin Mimetic Romiplostim with Standard of Care (SOC) in Patients with Immune Thrombocytopenia (ITP),

Long-Term Efficacy and Safety of Romiplostim for the Treatment of Patients with Chronic Immune Thrombocytopenia (ITP): 5-Year Update From An Open-Label Extension Study.

Long-Term Treatment with Romiplostim in Patients with Chronic Immune Thrombocytopenic Purpura (ITP): 3-Year Update from An Open-Label Extension Study

Long-Term Dosing of AMG 531 in Thrombocytopenic Patients with Immune Thrombocytopenic Purpura: 48-Week Update.

Email alerts

ASH Publications

American Society of Hematology

Tapering Thrombopoietin Receptor Agonists in Primary Immune Thrombocytopenia: Recommendations Based on the RAND/UCLA Modified Delphi Panel Method

Rate of Bleeding-Related Episodes (BREs) in Adult Patients with Primary Immune Thrombocytopenic Pupura (ITP): A Population-Based Retrospective Cohort Study of Administrative Medical Claims Data in the United States (US)

Integrated Analysis of Long Term Safety in Patients (pts) with Chronic Immune Thrombocytopenia (ITP) Treated with Romiplostim.

Use of Rituximab in a Study Comparing the Thrombopoietin Mimetic Romiplostim with Standard of Care (SOC) in Patients with Immune Thrombocytopenia (ITP),

Long-Term Efficacy and Safety of Romiplostim for the Treatment of Patients with Chronic Immune Thrombocytopenia (ITP): 5-Year Update From An Open-Label Extension Study.

Long-Term Treatment with Romiplostim in Patients with Chronic Immune Thrombocytopenic Purpura (ITP): 3-Year Update from An Open-Label Extension Study

Long-Term Dosing of AMG 531 in Thrombocytopenic Patients with Immune Thrombocytopenic Purpura: 48-Week Update.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only